Letís Heal™ is the result of 75 years experience in developing our products to help you test, protect, promote and comfort the wound towards healing.


WOUNDCHEK™ Protease Status

WOUNDCHEK™ Protease Status

Why test for EPA?

  • Chronic wounds with EPA (elevated protease activity) have a 90%
    probability they won’t heal1 (without appropriate intervention)
  • 28% of non-healing wounds have EPA1there are no visual cues to detect EPA2,3
  • Non-healing wounds cost billions to the healthcare system4,5

So, how do you know which wounds have EPA?

Developed to aid wound assessment and help clinicians target advanced wound care therapies more effectively, WOUNDCHEK Protease Status is able to detect EPA. As there are no visual cues for EPA, wounds with EPA have so far gone undetected2,3. WOUNDCHEK Protease Status will help clinicians establish within minutes which wounds may most benefit from a protease modulating therapy, ensuring appropriate and targeted use of these therapies.

Please refer in full to the Instructions for use leaflet provided in the product packaging, specific to your region.

Latest news:

WOUNDCHEK Protease Status product sizes:

WOUNDCHEK Protease Status Product sizes

Please refer to the relevant country website for correct product codes, sizes and
cartons configurations.

Systagenix is not responsible for the content of external websites.

The product information on this page is not intended for, or to be used by health care
professionals or users in the United States.

© Systagenix Wound Management 2013. WOUNDCHEK™ is a Registered Trademark of WOUNDCHEK™ Laboratories.
All other products referenced herein are acknowledged to be trademarks of their respective owners.



1. Serena T. et al. Protease activity levels associated with healing status of chronic wounds.Poster, Wounds UK 2011.

2. Snyder R. et al. A survey: The importance of proteases in wound healing and wound assessment. Poster, Wounds UK 2011.

3. International consensus. The role of proteases in wound diagnostics. An expert working group review. London: Wounds International, 2011.

4. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The healthcare costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–1795.

5. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care. 2003;26(8):2305–2310.

6. Instructions for Use 2011.

7. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol. 1994;130(4):489-493.

8. Consensus on Use of a Diagnostic Tool in Stalled Wounds to Identify Excess Protease Levels. The Protease Diagnostic Consensus Panel. Ostomy Wound Management. Ostomy Wound Management 2011;57(12): 36-48.